# Federal Register notice 2016-05959

> The Federal Register published notice 2016-05959, attributed to FDA and its parent HHS department, on 2016-03-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

- Evidence object: `story:federal-register-2016-05959:v1`
- Evidence domain: Regulatory
- Date in source: 2016-03-17
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-05959/
- JSON record: https://peptidescanner.com/evidence/v1/objects/federal-register-2016-05959-v1.json
- Content SHA-256: `c894b67b2f7ffc380a415a58a97ac04895ff2a0892e5c70f4d20d1e5f403e28d`

## Claims and source pins

### Headline

Federal Register notice 2016-05959 ([`federal-register-2016-05959-1d5042bed266`](#source-federal-register-2016-05959-1d5042bed266))

### Summary

The Federal Register published notice 2016-05959, attributed to FDA and its parent HHS department, on 2016-03-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2016-05959-1d5042bed266`](#source-federal-register-2016-05959-1d5042bed266))

### Paragraph 1

The Federal Register published notice 2016-05959, attributed to FDA and its parent HHS department, on 2016-03-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2016-05959-1d5042bed266`](#source-federal-register-2016-05959-1d5042bed266))

### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-05959-1d5042bed266`](#source-federal-register-2016-05959-1d5042bed266))

## Sources

<a id="source-federal-register-2016-05959-1d5042bed266"></a>
- **Federal Register notice 2016-05959 · published 2016-03-17 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-03-17/pdf/2016-05959.pdf) (`federal-register-2016-05959-1d5042bed266`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Federal Register notice 2016-05959." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/objects/federal-register-2016-05959-v1.json SHA-256: c894b67b2f7ffc380a415a58a97ac04895ff2a0892e5c70f4d20d1e5f403e28d.